Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors

Frequency Therapeutics Inc FREQ has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements.
The patients were evaluated 8 to 12 months following initial dosing.
Including the five initial responders, a total of nine subjects in the study (n=32) have shown statistically significant improvements in word recognition scores, a key measure of speech perception, at time points between 90 days and one year.
Of the five subjects with a statistically significant response at day-90, the four who returned for evaluation had scores that remained above their baseline word recognition measures.
However, they were below the threshold for statistical significance.
FX-322 is Frequency's lead product candidate for the treatment of acquired SNHL.
FX-322 is designed to regenerate auditory sensory hair cells located in the inner ear's cochlea and potentially restore hearing in individuals with SNHL.
Read Next: Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing Loss.
Price Action: FREQ stock is down 5.21% at $6.92 during the market session on the last check Wednesday.